XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.23.1

License Agreements - Additional Information (Details) $ / shares in Units, $ in Thousands |  |  | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Oct. 19, 2020 USD ($) Product $ / shares shares | Aug. 03, 2020 USD ($) Product $ / shares shares | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) $ / shares shares | Mar. 31, 2023 USD ($) shares
License Agreements [Line Items] |  |  |  |  |
Number of licensed products obliged to develop and commercialize | Product | 1 | 1 |  |  |
Upfront payment shares issued | shares |  |  |  | 45,089,537 | 45,091,215
Upfront payment value |  |  |  | $ 5 | $ 5
Mirati Therapeutics, Inc |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
Number of period the agreement in effect |  | 10 years |  |  |
Mirati Therapeutics, Inc | Private Placement | Common Stock |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
Upfront payment shares issued | shares |  | 588,235 |  |  |
Upfront payment value |  | $ 13,000 |  |  |
Issue price per share | $ / shares |  | $ 34.00 |  |  |
Premium percentage |  | 10.00% |  |  |
Stock transfer restrictions period |  | 18 months |  |  |
Voronoi Inc. | Development And Regulatory Milestone |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
License agreement maximum milestone payment obligation to pay | $ 111,000 |  |  |  |
Voronoi Inc. | Commercial Milestone |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
License agreement maximum milestone payment obligation to pay | 225,000 |  |  |  |
Voronoi Inc. | Success Based Milestones |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
License agreement, additional milestone payment | $ 272,000 |  |  |  |
Voronoi Inc. | Private Placement | Acquired In-Process Research and Development Expense |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
License agreement charge related to acquired assets |  |  | $ 5,000 |  |
Voronoi Inc. | Private Placement | Common Stock |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
Upfront payment shares issued | shares | 283,259 |  |  |  |
Upfront payment value | $ 6,800 |  |  |  |
Issue price per share | $ / shares | $ 28.24 |  |  |  |
Premium percentage | 25.00% |  |  |  |
Upfront cash payment | $ 5,000 |  |  |  |
Pfizer collaboration [Member] |  |  |  |  |
License Agreements [Line Items] |  |  |  |  |
Upfront payment shares issued | shares |  |  |  | 5,376,344 |
Issue price per share | $ / shares |  |  |  | $ 4.65 |
Proceeds from issuance of common stock |  |  |  | $ 25,000 |

X
- Definition License agreement additional Milestone payment. + References No definition available. + Details
Name: | oric_LicenseAgreementAdditionalMilestonePayment
Namespace Prefix: | oric_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement charge related to acquired assets. + References No definition available. + Details
Name: | oric_LicenseAgreementChargeRelatedToAcquiredAssets
Namespace Prefix: | oric_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement maximum milestone payment obligation to pay. + References No definition available. + Details
Name: | oric_LicenseAgreementMaximumMilestonePaymentObligationToPay
Namespace Prefix: | oric_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreements. + References No definition available. + Details
Name: | oric_LicenseAgreementsLineItems
Namespace Prefix: | oric_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of licensed products obliged to develop and commercialize. + References No definition available. + Details
Name: | oric_NumberOfLicensedProductsObligedToDevelopAndCommercialize
Namespace Prefix: | oric_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of period the agreement in effect. + References No definition available. + Details
Name: | oric_NumberOfPeriodAgreementInEffect
Namespace Prefix: | oric_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Shares issued percentage of premium. + References No definition available. + Details
Name: | oric_SharesIssuedPercentageOfPremium
Namespace Prefix: | oric_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock transfer restrictions period. + References No definition available. + Details
Name: | oric_StockTransferRestrictionsPeriod
Namespace Prefix: | oric_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | oric_UpfrontCashPayment
Namespace Prefix: | oric_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=oric_MiratiTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=oric_VoronoiIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=oric_DevelopmentAndRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=oric_CommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=oric_SuccessBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=oric_AcquiredInProcessResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=oric_PfizerCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |